IPO

SinoMab's $223m IPO extends HK biotech craze

SinoMab pushes forward with what could be the fourth-largest biotech listing in Hong Kong this year as investors' appetite for the sector picks up.

SinoMab BioScience is set to become the tenth biotech listing in Hong Kong so far this year as it looks to raise HK$1.75 billion ($223 million) from an initial public offering.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media